Drug Manufacturers - Specialty & Generic
Compare Stocks
4 / 10Stock Comparison
AKAN vs CGC vs TLRY vs ACB
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
AKAN vs CGC vs TLRY vs ACB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1M | $122M | $660M | $195M |
| Revenue (TTM) | $2M | $294M | $1.17B | $361M |
| Net Income (TTM) | $-31M | $-327M | $-2.95B | $41M |
| Gross Margin | -43.7% | 22.8% | 28.0% | 62.7% |
| Operating Margin | -6.3% | -24.1% | -266.0% | 13.3% |
| Forward P/E | — | — | — | 164.2x |
| Total Debt | $353K | $348M | $451M | $104M |
| Cash & Equiv. | $4M | $114M | $304M | $184M |
AKAN vs CGC vs TLRY vs ACB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| Akanda Corp. (AKAN) | 100 | 0.0 | -100.0% |
| Canopy Growth Corpo… (CGC) | 100 | 1.5 | -98.5% |
| Tilray Brands, Inc. (TLRY) | 100 | 72.8 | -27.2% |
| Aurora Cannabis Inc. (ACB) | 100 | 8.6 | -91.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AKAN vs CGC vs TLRY vs ACB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AKAN is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 1.71
- Lower volatility, beta 1.71, Low D/E 8.3%, current ratio 1.39x
- Beta 1.71 vs TLRY's 2.03, lower leverage
CGC lags the leaders in this set but could rank higher in a more targeted comparison.
TLRY is the clearest fit if your priority is long-term compounding.
- -74.7% 10Y total return vs ACB's -92.0%
- +12.1% vs AKAN's -46.1%
ACB carries the broadest edge in this set and is the clearest fit for growth exposure and defensive.
- Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
- Beta 1.81, current ratio 4.31x
- 27.0% revenue growth vs AKAN's -61.3%
- 11.2% margin vs AKAN's -19.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.0% revenue growth vs AKAN's -61.3% | |
| Quality / Margins | 11.2% margin vs AKAN's -19.6% | |
| Stability / Safety | Beta 1.71 vs TLRY's 2.03, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +12.1% vs AKAN's -46.1% | |
| Efficiency (ROA) | 5.2% ROA vs AKAN's -380.2%, ROIC 0.7% vs -7.5% |
AKAN vs CGC vs TLRY vs ACB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
AKAN vs CGC vs TLRY vs ACB — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACB leads in 2 of 6 categories
TLRY leads 1 • AKAN leads 0 • CGC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ACB leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TLRY is the larger business by revenue, generating $1.2B annually — 730.4x AKAN's $2M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to AKAN's -19.6%. On growth, CGC holds the edge at +20.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $294M | $1.2B | $361M |
| EBITDAEarnings before interest/tax | -$8M | -$32M | -$3.0B | $71M |
| Net IncomeAfter-tax profit | -$31M | -$327M | -$2.9B | $41M |
| Free Cash FlowCash after capex | -$7M | -$86M | -$94M | -$31M |
| Gross MarginGross profit ÷ Revenue | -43.7% | +22.8% | +28.0% | +62.7% |
| Operating MarginEBIT ÷ Revenue | -6.3% | -24.1% | -2.7% | +13.3% |
| Net MarginNet income ÷ Revenue | -19.6% | -111.0% | -2.5% | +11.2% |
| FCF MarginFCF ÷ Revenue | -4.4% | -29.3% | -8.1% | -8.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +20.9% | +3.0% | +6.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +88.4% | +83.8% | +70.7% | -94.5% |
Valuation Metrics
Evenly matched — AKAN and CGC and TLRY each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1M | $122M | $660M | $195M |
| Enterprise ValueMkt cap + debt − cash | -$2M | $293M | $806M | $136M |
| Trailing P/EPrice ÷ TTM EPS | -0.14x | -0.28x | -0.17x | 164.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 6.73x |
| Price / SalesMarket cap ÷ Revenue | 1.44x | 0.62x | 0.59x | 0.77x |
| Price / BookPrice ÷ Book value/share | 0.14x | 0.34x | 0.25x | 0.43x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Profitability & Efficiency
ACB leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-15 for AKAN. AKAN carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs TLRY's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -15.1% | -43.1% | -136.5% | +7.2% |
| ROA (TTM)Return on assets | -3.8% | -29.5% | -100.6% | +5.2% |
| ROICReturn on invested capital | -7.5% | -10.2% | -66.2% | +0.7% |
| ROCEReturn on capital employed | -3.0% | -12.4% | -78.1% | +0.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.08x | 0.72x | 0.22x | 0.17x |
| Net DebtTotal debt minus cash | -$3M | $235M | $147M | -$80M |
| Cash & Equiv.Liquid assets | $4M | $114M | $304M | $184M |
| Total DebtShort + long-term debt | $352,814 | $348M | $451M | $104M |
| Interest CoverageEBIT ÷ Interest expense | -47.93x | -7.79x | -89.43x | 6.27x |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TLRY five years ago would be worth $3,498 today (with dividends reinvested), compared to $1 for AKAN. Over the past 12 months, TLRY leads with a +1209.3% total return vs AKAN's -46.1%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs AKAN's -80.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +277.9% | -5.0% | -41.8% | -21.0% |
| 1-Year ReturnPast 12 months | -46.1% | -12.4% | +1209.3% | -25.3% |
| 3-Year ReturnCumulative with dividends | -99.3% | -91.4% | +103.6% | -47.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -99.6% | -65.0% | -96.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -94.3% | -74.7% | -92.0% |
| CAGR (3Y)Annualised 3-year return | -80.5% | -55.9% | +26.7% | -19.2% |
Risk & Volatility
Evenly matched — AKAN and ACB each lead in 1 of 2 comparable metrics.
Risk & Volatility
AKAN is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACB currently trades 51.4% from its 52-week high vs AKAN's 20.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 1.90x | 2.03x | 1.81x |
| 52-Week HighHighest price in past year | $185.80 | $2.38 | $15.70 | $6.67 |
| 52-Week LowLowest price in past year | $1.41 | $0.84 | $0.35 | $3.07 |
| % of 52W HighCurrent price vs 52-week peak | +20.0% | +47.5% | +36.1% | +51.4% |
| RSI (14)Momentum oscillator 0–100 | 61.0 | 52.9 | 37.9 | 52.2 |
| Avg Volume (50D)Average daily shares traded | 2.7M | 10.4M | 4.7M | 979K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CGC as "Hold", TLRY as "Hold", ACB as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs 72.6% for ACB (target: $6).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $14.47 | $10.00 | $5.92 |
| # AnalystsCovering analysts | — | 26 | 20 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
ACB leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 1 (Total Returns). 2 tied.
AKAN vs CGC vs TLRY vs ACB: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is AKAN or CGC or TLRY or ACB a better buy right now?
For growth investors, Aurora Cannabis Inc.
(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus -61. 3% for Akanda Corp. (AKAN). Aurora Cannabis Inc. (ACB) offers the better valuation at 164. 2x trailing P/E, making it the more compelling value choice. Analysts rate Canopy Growth Corporation (CGC) a "Hold" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AKAN or CGC or TLRY or ACB?
Over the past 5 years, Tilray Brands, Inc.
(TLRY) delivered a total return of -65. 0%, compared to -100. 0% for Akanda Corp. (AKAN). Over 10 years, the gap is even starker: TLRY returned -74. 7% versus AKAN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AKAN or CGC or TLRY or ACB?
By beta (market sensitivity over 5 years), Akanda Corp.
(AKAN) is the lower-risk stock at 1. 71β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 19% more volatile than AKAN relative to the S&P 500. On balance sheet safety, Akanda Corp. (AKAN) carries a lower debt/equity ratio of 8% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — AKAN or CGC or TLRY or ACB?
By revenue growth (latest reported year), Aurora Cannabis Inc.
(ACB) is pulling ahead at 27. 0% versus -61. 3% for Akanda Corp. (AKAN). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, AKAN leads at 172. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AKAN or CGC or TLRY or ACB?
Aurora Cannabis Inc.
(ACB) is the more profitable company, earning 0. 5% net margin versus -489. 6% for Akanda Corp. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -523. 8% for AKAN. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AKAN or CGC or TLRY or ACB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AKAN or CGC or TLRY or ACB better for a retirement portfolio?
For long-horizon retirement investors, Akanda Corp.
(AKAN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AKAN: -100. 0%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AKAN and CGC and TLRY and ACB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AKAN is a small-cap quality compounder stock; CGC is a small-cap quality compounder stock; TLRY is a small-cap quality compounder stock; ACB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.